Telemonitoring for the Management of Patients with Heart Failure.

IF 4.2 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Cardiac Failure Review Pub Date : 2020-04-21 eCollection Date: 2020-03-01 DOI:10.15420/cfr.2019.20
Ferdinando Iellamo, Barbara Sposato, Maurizio Volterrani
{"title":"Telemonitoring for the Management of Patients with Heart Failure.","authors":"Ferdinando Iellamo,&nbsp;Barbara Sposato,&nbsp;Maurizio Volterrani","doi":"10.15420/cfr.2019.20","DOIUrl":null,"url":null,"abstract":"<p><p>Advances in technology now make it possible to manage heart failure (HF) from a remote to a telemonitoring approach using either noninvasive solutions or implantable devices. Nowadays, it is possible to monitor at-home parameters that can be recorded, stored and remotely transmitted to physicians, allowing them to make decisions for therapeutic modification, hospitalization or access to the emergency room. Standalone systems are available that are equipped with self-intelligence and are able to acquire and elaborate data that can inform the remote physician of impending decompensation before it results in additional complications. The development of miniature implantable devices, which could measure haemodynamic variables and transmit them to a monitor outside the body, offers the possibility for the physician to obtain more frequent evaluations of HF patients and the opportunity to take these data into account in management decisions. At present, several telemonitoring devices are available, but the only Food and Drug Administration-approved system is the cardio-microelectromechanical system, which is an implantable pulmonary arterial pressure (PAP) monitoring device that allows a direct monitoring of the PAP via a sensor implanted in the pulmonary artery. This information is then uploaded to a web-based interface from which healthcare providers can track the results and manage patients. At present, the challenge point for telemedicine management of HF is to find the more relevant biological parameter to monitor the clinical status.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e07"},"PeriodicalIF":4.2000,"publicationDate":"2020-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/03/ae/cfr-06-e07.PMC7199126.pdf","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiac Failure Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15420/cfr.2019.20","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/3/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 4

Abstract

Advances in technology now make it possible to manage heart failure (HF) from a remote to a telemonitoring approach using either noninvasive solutions or implantable devices. Nowadays, it is possible to monitor at-home parameters that can be recorded, stored and remotely transmitted to physicians, allowing them to make decisions for therapeutic modification, hospitalization or access to the emergency room. Standalone systems are available that are equipped with self-intelligence and are able to acquire and elaborate data that can inform the remote physician of impending decompensation before it results in additional complications. The development of miniature implantable devices, which could measure haemodynamic variables and transmit them to a monitor outside the body, offers the possibility for the physician to obtain more frequent evaluations of HF patients and the opportunity to take these data into account in management decisions. At present, several telemonitoring devices are available, but the only Food and Drug Administration-approved system is the cardio-microelectromechanical system, which is an implantable pulmonary arterial pressure (PAP) monitoring device that allows a direct monitoring of the PAP via a sensor implanted in the pulmonary artery. This information is then uploaded to a web-based interface from which healthcare providers can track the results and manage patients. At present, the challenge point for telemedicine management of HF is to find the more relevant biological parameter to monitor the clinical status.

心衰患者的远程监护管理。
现在,技术的进步使得使用无创解决方案或植入式设备从远程到远程监测的方法来管理心力衰竭(HF)成为可能。如今,可以在家中监测参数,这些参数可以被记录、存储并远程传输给医生,使他们能够决定是否修改治疗方案、住院治疗或进入急诊室。独立系统配备了自我智能,能够获取和详细的数据,可以在导致额外并发症之前通知远程医生即将发生的失代偿。微型植入式装置的发展,可以测量血流动力学变量并将其传输到体外的监视器,为医生获得更频繁的心衰患者评估提供了可能,并有机会在管理决策中考虑这些数据。目前,有几种远程监测设备可用,但唯一获得食品和药物管理局批准的系统是心脏微机电系统,这是一种植入式肺动脉压(PAP)监测设备,可以通过植入肺动脉的传感器直接监测PAP。然后将这些信息上传到基于web的界面,医疗保健提供者可以从中跟踪结果并管理患者。目前,心衰远程医疗管理的挑战点是寻找更相关的生物学参数来监测临床状态。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.60
自引率
0.00%
发文量
31
审稿时长
9 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信